Optimization and formulation design of gels of Diclofenac and Curcumin for transdermal drug delivery by Box-Behnken statistical design

Journal of Pharmaceutical Sciences

Volumn 100, Issue 2, 2011, Pages 580-593

  Chaudhary, Hema ^a   Kohli, Kanchan ^a   Amin, Saima ^a   Rathee, Permender ^a   Kumar, Vikash ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Drug design; Drug transport; Factorial design; Formulation; Transdermal drug delivery

Indexed keywords

ALCOHOL; CURCUMIN; DICLOFENAC DIETHYLAMINE; POLYMER;

ANIMAL TISSUE; ARTICLE; CHEMICAL COMPOSITION; CONCENTRATION (PARAMETERS); DIFFUSION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG PENETRATION; DRUG RELEASE; GEL; MALE; NONHUMAN; PROCESS OPTIMIZATION; RAT; SKIN PERMEABILITY; STATISTICAL MODEL; VISCOSITY;

EID: 78650546947     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22292     Document Type: Article

References (64)

1. Ahad A, Aqil M, Kohli K, Chaudhary H, Sultana Y, Mujeeb M, Talegaonkar S. 2009. Chemical penetration enhancers: A patent review. Expert Opin Ther Patents 19(7):969-988.
2. Carlos S, Scott KF, Robert GJ. US Patent CA2299288, January 4, 2008.
3. Ranade VV. 1991. Drug delivery systems: Transdermal drug delivery. J Clin Pharmacol 31:401-418.
4. Gennaro AR. 2000. Remington's practice of pharmacy. 20th ed. Baltimore, MD: Lippincott Williams & Wilkins, pp 836.
5. Asbill CS, Michniak BB. 2000. Percutaneous penetration enhancers: Local versus transdermal activity. Pharm Sci Technol Today 3:36-41.
6. Dayal P, Pillay V, Babu RJ, Singh M. 2005. Box-Behnken experimental design in the development of a nasal drug delivery system of model drug hydroxyl urea: Characterization of viscosity, in vitro drug release, droplet size and dynamic surface tension. AAPS PharmSciTech 6:E573-E585.
7. Singh SK, Dodge J, Durrani MJ, Khan MA. 1995. Optimization and characterization of controlled release pellets coated with experimental latex: I. Anionic drug. Int J Pharm 125:243-255.
8. Singh B, Chakkal SK, Ahuja N. 2006. Formulation and optimization of controlled release mucoadhesive tablets of atenolol using response surface methodology. AAPS PharmSciTech 7:E1-E9.
9. Box GEP, Wilson KB. 1951. On the experimental attainment of multifactorial conditions. R Stat Soc 13:1-12.
10. Boza A, De la Cruz Y, Jordan G, Jauregui-Haza U, Aleman A, Caraballo I. 2000. Statistical optimization of a sustained release matrix tablet of lobenzarit disodium. Drug Dev Ind Pharm 26:1303-1307.
11. Sánchez-Lafuente C, Furlanetto S, Fernández-Arévalo M, Alvarez-Fuentes J, Rabasco AM, Faucci MT, Pinzauti S, Mura P. 2002. Didanosine extended-release matrix tablets: Optimization of formulation variables using statistical experimental design. Int J Pharm 237:107-118.
12. Govender S, Pillay V, Chetty DJ, Essack SY, Dangor CM, Govender T. 2005. Optimization and characterization of bioadhesive controlled release tetracycline microspheres. Int J Pharm 306:24-40.
13. Palamakula A, Nutan MTH, Khan MA. 2004. Response surface methodology for Optimization and characterization of limonene-based Coenzyme Q10 self-nanoemulsified capsule dosage form. APPS PharmSciTech 5:1-8.
14. Ragonese R, Macka M, Hughes J, Petocz P. 2002. The use of the Box-Behnken experimental design in the optimization and robustness testing of a capillary electrophoresis method for the analysis of ethambutol hydrochloride in a pharmaceutical formulation. J Pharm Biomed Anal 27:995-1007.
15. Rhee YS, Chang SY, Park CW, Chi SC, Park ES. 2008. Optimization of ibuprofen gel formulations using experimental design technique for enhanced transdermal penetration. Int J Pharm 364(1):14-20.
16. Agyralides GG, Dallas PP, Rekkas DM. 2004. Development and in vitro evaluation of furosemide transdermal formulations using experimental design techniques. Int J Pharm 281(1-2):35-43.
17. Gannu R, Yamsani VV, Yamsani SK, Palem CR, Yamsani MR. 2009. Optimization of hydrogels for transdermal delivery of lisinopril by Box-Behnken statistical design. AAPS PharmSciTech 10(2):505-514.
18. Mohamed MI. 2004. Optimization of chlorphenesin emulgel formulation. AAPS J 6(3):e26.
19. Giannakow SA, Dallas PP, Rekkas DM, Choulis NH. 1995. Development and in vitro evaluation of nitrendipine transdermal formulations using experimental design techniques. Int J Pharm 125:7-15.
20. Giannakou SA, Dallas PP, Rekkas DM, Choulis NH. 1998. Development and in vitro evaluation of nimodipine transdermal formulations using factorial design. Pharm Dev Technol 3(4):517-525.
21. John VA. 1979. The pharmacokinetics and metabolism of diclofenac sodium (Voltarol-TM) in animals and man. Rheumatol Rehabil Suppl 2:22-37.
22. Knutson K, Krill SL, Lambert WJ, Higuchi WI. 1987. Physicochemical aspects of transdermal permeation. J Control Release 6:59-74.
23. Kriwet K, Muller-Goymann CC. 1993. Binary diclofenac diethylamine-water systems, micelles, vesicles, and lyotropic liquid crystals. Eur J Pharm Biopharm 39(6):234-238.
24. Arora P, Mukherjee B. 2002. Design, development, physical, and in vitro and in vivo evaluation of transdermal patches containing diclofenac diethylammonium salt. J Pharm Sci 91:2076-2089.
25. Barry BW. 1991. The LPP theory of skin penetration enhancement. In In vitro percutaneous absorption: Principles, fundamentals, and applications; Bronaugh RL, Maibach HI, Eds., Prlando, FL: CRS Press, pp 165-185.
26. Kneep VM, Szoka FC, Guy RH. 1990. Controlled drug release from novel liposomal delivery system: II. Transdermal delivery characteristics. J Control Release 12:25-30.
27. Cappel MJ, Kreuter J. 1991. Effect of nanoparticles on transdermal drug delivery. J Microencapsul 8:369-374.
28. Lasch J, Laub R, Wohlarab W. 1991. How deep do intact liposomes penetrate into human skin? J Control Release 18:55-58.
29. Kweon JH, Chi SC, Park ES. 2004. Transdermal delivery of diclofenac using microemulsions. Arch Pharm Res 27(3):351-356.
30. Fang JY, Hung CF, Chiu HC, Wang JJ, Chan TF. 2003. Efficacy and irritancy of enhancers on the in-vitro and in-vivo percutaneous absorption of curcumin. J Pharm Pharmacol 55:593-601.
31. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, Steward WP. 2004. Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. Clin Cancer Res 10(20):6847-6854.
32. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. 1998. Influence of piperine on the pharmacokinetics of curcuminin animals and human volunteers. Planta Med 64(4):353-356.
33. Ravindranath V, Chandrasekhara N. 1980. Absorption and tissue distribution of curcumin in rats. Toxicology 16:259-265.
34. Cheng AL, Lin JK, Hsu MM, Lin JT, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Wu MS, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang UJ, Tsai CC, Hsieh CY. 2001. Phase I chemoprevention clinical trial of curcumin, a chemopreventive agent, in patients with high risk or pre-malignant lesions. Anticancer Res 21:2895-2900.
35. Asai A, Miyazawa T. 2000. Occurrence of orally administered curcuminoid as glucuronide and glucuronide/sulfate conjugates in rat plasma. Life Sci 67:2785-2793.
36. Patel NA, Patel NJ, Patel RP. 2009. Design and evaluation of transdermal drug delivery system for curcumin as an anti-inflammatory drug. Drug Dev Ind Pharm 35(2):234-242.
37. Ammon HPT, Wahl MA. 1991 Pharmacology of curcuma longa. Planta Med 57(1):7.
38. Anto RJ, Kuttan G, Babu KVD, Rajasekharan KN, Kuttan R. 1998. Antiinflammatory activity of natural and synthetic curcuminoids. Pharm Pharmacol Commun 4:103-106.
39. Bangham AD, Hill MW, Miller NGA. 1974. Preparation and use of liposome's as models of biological membranes. In Methods in membrane biology; Korn ED, Ed. Vol. 1. New York: Plenum Press, pp 1-64.
40. Tiyaboonchai W, Tungpradit W, Plianbangchang P. 2007. Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int J Pharm 337(1-2):299-306.
41. Vidyalakshmi K, Rashmi KN, Pramodkumar TM, Siddaramaiah K. 2004. Studies on formulation and in vitro evaluation of PVA/chitosan blend films for drug delivery. J Macromol Sci Pure Appl Chem 41(10):1115-1122.
42. Kumar V, Lewis SA, Mutalik S, Shenoy DB, Venkatesh M, Udupa N. 2002. Biodegradable microspheres of curcumin for treatment of inflammation. Indian J Physiol Pharmacol 46(2):209-217.
43. Wang X, Jiang Y, Wang YW, Huang MT, Ho CT, Huang Q. 2008. Enhancing anti-inflammation activity of curcumin through o/w nanoemulsions. Food Chem 108(2):419-424.
44. Macedo T, Block LH, Shukla AJ. 1993. Release of tolmetin from carbomer gel systems. Drug Dev Ind Pharm 19(8):887-902.
45. Dittgen M, Durani M, Lehmann K. 1997. Acrilyc polymers: A review of pharmaceutical applications. STP Pharma Sci 7:403-437.
46. Skiba M, Skiba-Lahiani M, Marchais H, Duclos R, Arnaud P. 2000. Stability assessment of ketoconazole in aqueous formulations. Int J Pharm 198:1-6.
47. Box GEP, Behnken DW. 1960. Some new three level designs for the study of quantitative variables. Technometrics 2:455-475.
48. Mutimier MN, Reffkin C, Hill JA, Marry E, Glickman ME, Cry GN. 1965. Modern ointment base technology II. J Am Pharm Assoc Sci 45:212-220.
49. Krishnaiah, YS, Satyanarayana V, Bhasker P. 2003. Enhanced percutaneous permeability of nicardipine hydrochloride by carvone across the rat abdominal skin. Drug Dev Ind Pharm 29(2): 191.
50. Clearly GW. 1984. Transdermal controlled release systems. In Medical applications of controlled release; Langer RS, Wise DS, Eds. Vol. 1. Boca Raton, FL: CRC Press, pp 204-251.
51. Lucero MJ, Vigo J, Leon MJ. 1994. A study of shear and compression deformations on hydrophilic gels of tretinoin. Int J Pharm 106:25-133.
52. Abd El-Bary A, Tayel S, Amin SY, Osman A. 1992. Bioavailability of salbutamol sulphate from different suppository formulations. Egypt J Pharm Sci 33:1031-1043.
53. Ebdon JR, Jones MS. 1996. Flame retardants (Overview). In Polymeric materials encyclopedia; Salomone JC, ed. Vol. 4. Boca Raton, London: CRC Press, pp 2397-2411.
54. Levang AK, Zhao K, Singh J. 1999. Effect of ethanol/propylene glycol on the in vitro percutaneous absorption of aspirin, biophysical changes and macroscopic barrier properties of the skin. Int J Pharmaceut 181(2):255-263.
55. Levison KK, Takayama K, Isowa K, Okabe K, Nagai T. 1994. Formulation optimization of indomethacin gels containing a combination of three kinds of cyclic monoterpenes as percutaneous penetration enhancers. J Pharm Sci 83(9):1367-1372.
56. Chattaraj SC, Walker RB. 1995. Penetration enhancer classification. In Percutaneous penetration enhancers; Smith EW, Maibach HI, Eds. New York: CRC Press, pp 5-15.
57. Cornwell PA, Barry BW, Stoddart CP, Bouwstra JA. 1994. Wide-angle X-ray diffraction of human stratum corneum: Effects of hydration and terpene enhancer treatment. J Pharm Pharmacol 46:938-950.
58. Arellano A, Santoyo S, Martin C, Ygartua P. 1998. Influence of propylene glycol and isopropyl myristate on the in vitro percutaneous penetration of diclofenac sodium from carbopol gels. Eur J Pharm Sci 7:129-135.
59. Krishnaiah YSR, Satyanarayana V, Karthikeyan RS. 2002. Effect of the solvent system on the in vitro permeability of nicardipine hydrochloride through excised rat epidermis. J Pharm Pharmaceuti Sci 5:123-130.
60. Barry BW. 1983. Properties that influence percutaneous absorption. In Dermatological Formulations; Barry BW, Ed. New York: Marcel Dekker, pp 127-233.
61. Sarpotdar PP, Zatz JL 1986. Evaluation of penetration enhancement of lidocaine by nonionic surfactants through hairless mouse skin in vitro. J Pharm Sci 75:176-181.
62. Yamane MA, Williams AC, Barry BW. 1995. Terpenes penetration enhancers in propylene glycol/water co-solvent systems: Effectiveness and mechanism of action. J Pharm Pharmacol 47:978-989.
63. Goodman M, Barry BW. 1989. Action of penetration enhancers on human stratum corneum as assessed by differential scanning calorimetry. In Percutaneous absorption, mechanisms, methodology, drug delivery; Bronaugh RL, Maibach HI, Eds. New York: Marcel Dekker, pp 567-593.
64. Rao PR, Diwan PV. 1998. Formulation and in vitro evaluation of polymeric films of diltiazem hydrochloride and indomethacin for transdermal administration. Drug Dev Ind Pharm 24:327-336.